Evaluation of the Stability of Fluoxetine in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date

Peacock, Gina F; Sauvageot, Jurgita

Abstract

Evaluation of the Stability of Fluoxetine in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date

Author(s): Peacock Gina F, Sauvageot Jurgita

Issue: May/Jun 2014 - Volume 18, Number 3

View All Articles in Issue

Page(s): 253-255

Download in electronic PDF format for $75

Abstract

Fluoxetine is a commonly prescribed psychotropic medication for a variety of behavioral diagnoses in veterinary practice, and fluoxetine in Pluronic lecithin organogel has been used successfully in treating inappropriate urine spraying in felines. Historically, pharmacists have assigned a variety of beyond-use dates to extemporaneously compound drugs in Pluronic lecithin organogel. The objective of this study was to evaluate the stability of fluoxetine in Pluronic lecithin organogel over a period of six months and to determine an appropriate beyond-use date. A stability-indicating high-performance liquid chromatography method for fluoxetine in Pluronic lecithin organogel was validated in our laboratory. Fluoxetine-Pluronic lecithin organogel 50 mg/mL was prepared by a local compounding pharmacy and analyzed by high-performance liquid chromatograph at 0, 7, 14, 21, 28, 45, 60, 90, and 180 days. Physical stability was also assessed by visual observation. At each time point percent of initial concentration was calculated. The beyond-use date was determined as the time period that the samples maintained at least 90 percent of the initial concentration. At 180 days, the mean percent of initial concentration was 99 ± 1.5 and, visually, the fluoxetine-Pluronic lecithin organogel retained the original color and consistency, without detectable separation of the different phases of Pluronic lecithin organogel. Since fluoxetine was physically stable and retained greater than 90 percent of initial concentration in Pluronic lecithin organogel for 180 days when stored at room temperature and protected from light, a beyonduse date of 180 days is appropriate.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
May/Jun 2014 Pg. 253-255	Evaluation of the Stability of Fluoxetine in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date Author(s): Peacock Gina F, Sauvageot Jurgita
Jul/Aug 2014 Pg. 345-347	Evaluation of the Stability of Promethazine Hydrochloride in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date Author(s): Peacock Gina F, Sauvageot Jurgita
Jul/Aug 2014 Pg. 348-350	Evaluation of the Stability of Ketoprofen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date Author(s): Peacock Gina F, Sauvageot Jurgita, Addo Richard T
Sep/Oct 2018 Pg. 409	Fluoxetine 50 mg/mL in Pluronic Lecithin Organogel Author(s): Allen Loyd V Jr
May/Jun 2003 Pg. 180-183	The History of Pluronic Lecithin Organogel: An Interview With Marty Jones, BSPharm, FACA, FIACP Author(s): Allen Loyd V Jr
May/Jun 2014 Pg. 256-261	Preparation and In Vitro Evaluation of a Pluronic Lecithin Organogel Containing Ricinoleic Acid for Transdermal Delivery Author(s): Boddu Sai HS, Bonam Sindhu Prabha, Wei Yangjie, Alexander Kenneth
Jan/Feb 2022 Pg. 65-71	Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management Author(s): Hong Eun Ji, Sumanasekera Wasana, Le Uyen Minh
Mar/Apr 2004 Pg. 101-105	Pluronic Lecithin Organogel for Local Delivery of Anti-Inflammatory Drugs Author(s): Frankum James, Ramsay Dale, Das Nandita G, Das Sudip K
Jul/Aug 2021 Pg. 322	BHR in PLO Gel (Benadryl, Haldol, and Reglan in Pluronic Lecithin Organogel) Author(s): Allen Loyd V Jr
May/Jun 2005 Pg. 242-246	Bioavailability of Promethazine in a Topical Pluronic Lecithin Organogel: A Pilot Study Author(s): Glisson James K, Wood Rebecca L, Kyle Patrick B, Cleary John D
Jan/Feb 2012 Pg. 62-63	The Use of Pluronic Lecithin Organogels in the Transdermal Delivery of Drugs Author(s): Bramwell Bethany L, Williams LaVonn A
Sep/Oct 2012 Pg. 428-430	Evaluation of the Stability of Acetaminophen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-Use Date Author(s): Peacock Gina F, Sauvageot Jurgita
May/Jun 2013 Pg. 247-253	Effect of Formulation pH on Transdermal Penetration of Antiemetics Formulated in Poloxamer Lecithin Organogel Author(s): Woodall Rachel, Arnold John J, McKay Doug, Abill C Scott
Nov/Dec 2010 Pg. 522-525	Stability of Methimazole in Poloxamer Lecithin Organogel to Determine Beyond-Use Date Author(s): Pignato Alyssa, Pankaskie Marvin, Birnie Christine
May/Jun 2009 Pg. 244	Morphine Sulfate 50 mg/mL in Pluronic Lecithin Organogel Author(s): Allen Loyd V Jr
May/Jun 2009 Pg. 245	Oxycodone Hydrochloride 10 mg/mL in Pluronic Lecithin Organogel Author(s): Allen Loyd V Jr
May/Jun 2012 Pg. 248-252	In Vitro Percutaneous Absorption of Ketoprofen and Testosterone: Comparison of Pluronic Lecithin Organogel vs. Pentravan Cream Author(s): Lehman Paul A, Raney Sam G
Jan/Feb 2021 Pg. 73-81	Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design Author(s): Patel Gopesh, Davis Countaney, Liu Yi, Ip Kendice, Debideen Krystal E, Anderson Stephanie, Byrne Robert, Herr Dylan, Rhoads Melissa Merrell, Caputo Ross, Banov Daniel, Bassani August S
May/Jun 2004 Pg. 185	Clonidine HCl 0.2%/Gabapentin 6%/Ketamine HCl 10% in Pluronic Lecithin Organogel (PLO) Author(s): Hinkle Amanda R, Newton Gail D
Sep/Oct 2001 Pg. 374	Estriol 2-mg/mL and Estradiol 0.5-mg/mL in Pluronic Lecithin Organogel (PLO) Author(s): Allen Loyd V Jr